The present subject matter provides urea biosensors as well as compositions, devices, and methods comprising such biosensors.

The present description relates to a method for identifying a patient who is eligible for an intensification of heart failure therapy. Furthermore, the description relates to a method for pikej3optimizing B-type natriuretic peptide (BNP) and/or N-terminal pro B-type natriuretic peptide (NT-proBNP)-type peptide guided heart failure therapy. The methods are based on the measurement of the level of at least one marker in a sample from a patient who has heart failure and who receives B-type natriuretic peptide (BNP) and/or N-terminal pro B-type natriuretic peptide (NT-proBNP)-type peptide guided heart failure therapy. Further described are kits and devices adapted to carry out the described method.

The present description relates to a method for identifying a patient who is eligible for an intensification of heart failure therapy. Furthermore, the description relates to a method for pikej3optimizing B-type natriuretic peptide (BNP) and/or N-terminal pro B-type natriuretic peptide (NT-proBNP)-type peptide guided heart failure therapy. The methods are based on the measurement of the level of at least one marker in a sample from a patient who has heart failure and who receives B-type natriuretic peptide (BNP) and/or N-terminal pro B-type natriuretic peptide (NT-proBNP)-type peptide guided heart failure therapy. Further described are kits and devices adapted to carry out the described method.

The present invention relates to a small urea sensor module, configured such that a urease-immobilized insoluble porous support, in which urease is immobilized on a porous support made of a natural polymer such as silk fibroin, etc. or a synthetic polymer, is mounted in a fluidic chamber and also such that the electrode surface of a three-electrode strip is exposed to the bottom surface of the chamber. This urea sensor is essential for the evaluation of the regenerated solution from a portable peritoneal dialysis fluid regeneration system and has advantages such as portability, reproducibility, mass productivity and simplicity, which will greatly contribute to disease management of patients with chronic renal disease.

The present invention relates to a small urea sensor module, configured such that a urease-immobilized insoluble porous support, in which urease is immobilized on a porous support made of a natural polymer such as silk fibroin, etc. or a synthetic polymer, is mounted in a fluidic chamber and also such that the electrode surface of a three-electrode strip is exposed to the bottom surface of the chamber. This urea sensor is essential for the evaluation of the regenerated solution from a portable peritoneal dialysis fluid regeneration system and has advantages such as portability, reproducibility, mass productivity and simplicity, which will greatly contribute to disease management of patients with chronic renal disease.

The present description relates to a method for identifying a patient who is eligible for an intensification of heart failure therapy. Furthermore, the description relates to a method for optimizing B type natriuretic peptide (BNP) and/or N-terminal pro B-type natriuretic peptide (NT-proBNP)-type peptide guided heart failure therapy. The methods are based on the measurement of the level of at least one marker in a sample from a patient who has heart failure and who receives B-type natriuretic peptide (BNP) and/or N-terminal pro B-type natriuretic peptide (NT-proBNP)-type peptide guided heart failure therapy. Further described are kits and devices adapted to carry out the described method.

The present description relates to a method for identifying a patient who is eligible for an intensification of heart failure therapy. Furthermore, the description relates to a method for optimizing B type natriuretic peptide (BNP) and/or N-terminal pro B-type natriuretic peptide (NT-proBNP)-type peptide guided heart failure therapy. The methods are based on the measurement of the level of at least one marker in a sample from a patient who has heart failure and who receives B-type natriuretic peptide (BNP) and/or N-terminal pro B-type natriuretic peptide (NT-proBNP)-type peptide guided heart failure therapy. Further described are kits and devices adapted to carry out the described method.

An arrangement, a method, and a measurement indicator, configured to measure urea in a milk sample of an animal (100). The arrangement includes a reference indicator, impregnated with a halochromic substance configured to adjust colour, based on a level of hydroxide ions of a first sub milk sample; a measurement indicator, impregnated with the halochromic substance of the reference indicator, and prepared with an enzyme configured to convert urea of a second sub milk sample, into at least one chemical substance, which in turn will influence the level of hydroxide ions of the second sub sample; a sensor configured to capture a first image of the reference indicator, and a second image of the measurement indicator; and a control unit configured to determine colour difference between the images; and configured to convert the determined colour difference into urea amount in the milk sample.

Apparatus and methods for measuring a concentration of a target molecule from a biological sample are disclosed. For example, the apparatus comprises a porous pad, which is impregnated with a solution containing at least one agent and contains an unfilled capillary matrix, a housing for the porous pad, and a membrane that covers the porous pad.

Apparatus and methods for measuring a concentration of a target molecule from a biological sample are disclosed. For example, the apparatus comprises a porous pad, which is impregnated with a solution containing at least one agent and contains an unfilled capillary matrix, a housing for the porous pad, and a membrane that covers the porous pad.